nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Dexamethasone—multiple sclerosis	0.173	0.346	CbGbCtD
Bosentan—CYP3A4—Fingolimod—multiple sclerosis	0.0731	0.146	CbGbCtD
Bosentan—CYP3A4—Methylprednisolone—multiple sclerosis	0.0471	0.0939	CbGbCtD
Bosentan—CYP3A4—Triamcinolone—multiple sclerosis	0.0357	0.0712	CbGbCtD
Bosentan—CYP3A4—Mitoxantrone—multiple sclerosis	0.0344	0.0685	CbGbCtD
Bosentan—CYP2C9—Dexamethasone—multiple sclerosis	0.0306	0.0611	CbGbCtD
Bosentan—CYP3A4—Betamethasone—multiple sclerosis	0.0306	0.0611	CbGbCtD
Bosentan—CYP3A4—Prednisolone—multiple sclerosis	0.0302	0.0602	CbGbCtD
Bosentan—CYP3A4—Prednisone—multiple sclerosis	0.0285	0.0569	CbGbCtD
Bosentan—CYP3A4—Dexamethasone—multiple sclerosis	0.0178	0.0355	CbGbCtD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00053	0.00362	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CCR1—multiple sclerosis	0.000525	0.00359	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CXCL13—multiple sclerosis	0.000525	0.00359	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CCL3—multiple sclerosis	0.000523	0.00357	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000523	0.00357	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000523	0.00357	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.000519	0.00354	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000516	0.00352	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—S1PR1—multiple sclerosis	0.000511	0.00349	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—PTGER4—multiple sclerosis	0.000504	0.00344	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.000492	0.00336	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CXCR3—multiple sclerosis	0.000486	0.00332	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.000479	0.00327	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—RGS1—multiple sclerosis	0.000479	0.00327	CbGpPWpGaD
Bosentan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000475	0.00324	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.000474	0.00324	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.000473	0.00323	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CCR2—multiple sclerosis	0.000473	0.00323	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000467	0.00319	CbGpPWpGaD
Bosentan—EDNRB—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000467	0.00318	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000457	0.00312	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—MAPK1—multiple sclerosis	0.000457	0.00312	CbGpPWpGaD
Bosentan—EDNRB—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000456	0.00312	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—GPR65—multiple sclerosis	0.000454	0.0031	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000445	0.00304	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000444	0.00303	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CNR1—multiple sclerosis	0.000437	0.00298	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—RGS1—multiple sclerosis	0.000435	0.00297	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000429	0.00293	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000429	0.00293	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.000427	0.00292	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CCR1—multiple sclerosis	0.000415	0.00283	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000415	0.00283	CbGpPWpGaD
Bosentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000414	0.00283	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—GPR65—multiple sclerosis	0.000412	0.00281	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.00041	0.0028	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000403	0.00275	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.0004	0.00273	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—LINGO1—multiple sclerosis	0.000398	0.00272	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000398	0.00272	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000398	0.00272	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CXCL10—multiple sclerosis	0.000393	0.00268	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CXCL13—multiple sclerosis	0.000377	0.00257	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CCR1—multiple sclerosis	0.000377	0.00257	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000375	0.00256	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CCL3—multiple sclerosis	0.000374	0.00256	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000369	0.00252	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—S1PR1—multiple sclerosis	0.000366	0.0025	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—PTGER4—multiple sclerosis	0.00036	0.00246	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CXCR3—multiple sclerosis	0.000348	0.00238	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000346	0.00236	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000346	0.00236	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TAGAP—multiple sclerosis	0.000345	0.00236	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—RGS1—multiple sclerosis	0.000343	0.00234	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000341	0.00233	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000341	0.00233	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CCR2—multiple sclerosis	0.000339	0.00231	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CCL5—multiple sclerosis	0.000338	0.00231	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000334	0.00228	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000334	0.00228	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000327	0.00223	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—GPR65—multiple sclerosis	0.000325	0.00222	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000318	0.00217	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000313	0.00214	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CNR1—multiple sclerosis	0.000313	0.00213	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—RGS1—multiple sclerosis	0.000311	0.00212	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000306	0.00209	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CCR5—multiple sclerosis	0.000305	0.00208	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—S1PR1—multiple sclerosis	0.000302	0.00206	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000297	0.00203	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CCR1—multiple sclerosis	0.000297	0.00203	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—GPR65—multiple sclerosis	0.000295	0.00201	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—GPC5—multiple sclerosis	0.000294	0.00201	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000287	0.00196	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—LINGO1—multiple sclerosis	0.000285	0.00195	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000285	0.00194	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CXCL10—multiple sclerosis	0.000281	0.00192	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000275	0.00188	CbGpPWpGaD
Bosentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000273	0.00186	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CCR1—multiple sclerosis	0.00027	0.00184	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CXCL13—multiple sclerosis	0.00027	0.00184	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000269	0.00183	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CCL3—multiple sclerosis	0.000268	0.00183	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CCR2—multiple sclerosis	0.000267	0.00183	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PTGER4—multiple sclerosis	0.000258	0.00176	CbGpPWpGaD
Bosentan—Angioedema—Betamethasone—multiple sclerosis	0.000257	0.00073	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—RGS1—multiple sclerosis	0.000257	0.00175	CbGpPWpGaD
Bosentan—Stomatitis—Methotrexate—multiple sclerosis	0.000255	0.000725	CcSEcCtD
Bosentan—Angiopathy—Prednisone—multiple sclerosis	0.000255	0.000725	CcSEcCtD
Bosentan—Conjunctivitis—Methotrexate—multiple sclerosis	0.000254	0.000723	CcSEcCtD
Bosentan—Immune system disorder—Prednisone—multiple sclerosis	0.000254	0.000722	CcSEcCtD
Bosentan—Oedema—Triamcinolone—multiple sclerosis	0.000253	0.000718	CcSEcCtD
Bosentan—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000253	0.000718	CcSEcCtD
Bosentan—Vertigo—Dexamethasone—multiple sclerosis	0.000252	0.000717	CcSEcCtD
Bosentan—Vertigo—Betamethasone—multiple sclerosis	0.000252	0.000717	CcSEcCtD
Bosentan—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000252	0.000717	CcSEcCtD
Bosentan—Syncope—Dexamethasone—multiple sclerosis	0.000252	0.000716	CcSEcCtD
Bosentan—Syncope—Betamethasone—multiple sclerosis	0.000252	0.000716	CcSEcCtD
Bosentan—ABCB11—Metabolism—SRM—multiple sclerosis	0.000251	0.00172	CbGpPWpGaD
Bosentan—Infection—Triamcinolone—multiple sclerosis	0.000251	0.000714	CcSEcCtD
Bosentan—Infection—Methylprednisolone—multiple sclerosis	0.000251	0.000712	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—CXCR3—multiple sclerosis	0.00025	0.0017	CbGpPWpGaD
Bosentan—Haematuria—Methotrexate—multiple sclerosis	0.00025	0.000709	CcSEcCtD
Bosentan—Shock—Triamcinolone—multiple sclerosis	0.000249	0.000707	CcSEcCtD
Bosentan—Insomnia—Prednisolone—multiple sclerosis	0.000249	0.000706	CcSEcCtD
Bosentan—Shock—Methylprednisolone—multiple sclerosis	0.000248	0.000705	CcSEcCtD
Bosentan—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000248	0.000703	CcSEcCtD
Bosentan—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000247	0.000703	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—TAGAP—multiple sclerosis	0.000247	0.00169	CbGpPWpGaD
Bosentan—Loss of consciousness—Betamethasone—multiple sclerosis	0.000247	0.000702	CcSEcCtD
Bosentan—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000247	0.000702	CcSEcCtD
Bosentan—Epistaxis—Methotrexate—multiple sclerosis	0.000247	0.000701	CcSEcCtD
Bosentan—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000247	0.000701	CcSEcCtD
Bosentan—Paraesthesia—Prednisolone—multiple sclerosis	0.000247	0.000701	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—CNR1—multiple sclerosis	0.000247	0.00168	CbGpPWpGaD
Bosentan—Tachycardia—Triamcinolone—multiple sclerosis	0.000247	0.000701	CcSEcCtD
Bosentan—Mental disorder—Prednisone—multiple sclerosis	0.000246	0.0007	CcSEcCtD
Bosentan—Nausea—Azathioprine—multiple sclerosis	0.000246	0.000699	CcSEcCtD
Bosentan—Tachycardia—Methylprednisolone—multiple sclerosis	0.000246	0.000699	CcSEcCtD
Bosentan—Skin disorder—Methylprednisolone—multiple sclerosis	0.000245	0.000696	CcSEcCtD
Bosentan—Erythema—Prednisone—multiple sclerosis	0.000245	0.000695	CcSEcCtD
Bosentan—Malnutrition—Prednisone—multiple sclerosis	0.000245	0.000695	CcSEcCtD
Bosentan—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000244	0.000694	CcSEcCtD
Bosentan—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000244	0.000693	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—GPR65—multiple sclerosis	0.000243	0.00166	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CCR2—multiple sclerosis	0.000243	0.00166	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CCL5—multiple sclerosis	0.000242	0.00165	CbGpPWpGaD
Bosentan—Asthenia—Mitoxantrone—multiple sclerosis	0.00024	0.000683	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000239	0.00163	CbGpPWpGaD
Bosentan—Anxiety—Betamethasone—multiple sclerosis	0.000238	0.000677	CcSEcCtD
Bosentan—Anxiety—Dexamethasone—multiple sclerosis	0.000238	0.000677	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—POMC—multiple sclerosis	0.000238	0.00163	CbGpPWpGaD
Bosentan—Discomfort—Dexamethasone—multiple sclerosis	0.000236	0.000672	CcSEcCtD
Bosentan—Discomfort—Betamethasone—multiple sclerosis	0.000236	0.000672	CcSEcCtD
Bosentan—Haemoglobin—Methotrexate—multiple sclerosis	0.000236	0.000671	CcSEcCtD
Bosentan—Hypotension—Methylprednisolone—multiple sclerosis	0.000236	0.00067	CcSEcCtD
Bosentan—Pain—Prednisolone—multiple sclerosis	0.000235	0.000668	CcSEcCtD
Bosentan—Haemorrhage—Methotrexate—multiple sclerosis	0.000235	0.000668	CcSEcCtD
Bosentan—Hepatitis—Methotrexate—multiple sclerosis	0.000235	0.000668	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—CCL2—multiple sclerosis	0.000233	0.00159	CbGpPWpGaD
Bosentan—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000232	0.000659	CcSEcCtD
Bosentan—Vision blurred—Prednisone—multiple sclerosis	0.000231	0.000655	CcSEcCtD
Bosentan—Urethral disorder—Methotrexate—multiple sclerosis	0.00023	0.000654	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00023	0.000654	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00023	0.000653	CcSEcCtD
Bosentan—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000229	0.000652	CcSEcCtD
Bosentan—Oedema—Betamethasone—multiple sclerosis	0.000229	0.000652	CcSEcCtD
Bosentan—Oedema—Dexamethasone—multiple sclerosis	0.000229	0.000652	CcSEcCtD
Bosentan—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000229	0.000652	CcSEcCtD
Bosentan—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000229	0.000651	CcSEcCtD
Bosentan—Insomnia—Triamcinolone—multiple sclerosis	0.000229	0.00065	CcSEcCtD
Bosentan—Insomnia—Methylprednisolone—multiple sclerosis	0.000228	0.000648	CcSEcCtD
Bosentan—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000228	0.00156	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000228	0.00156	CbGpPWpGaD
Bosentan—Infection—Dexamethasone—multiple sclerosis	0.000228	0.000647	CcSEcCtD
Bosentan—Infection—Betamethasone—multiple sclerosis	0.000228	0.000647	CcSEcCtD
Bosentan—Paraesthesia—Triamcinolone—multiple sclerosis	0.000227	0.000645	CcSEcCtD
Bosentan—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000226	0.000643	CcSEcCtD
Bosentan—Anaemia—Prednisone—multiple sclerosis	0.000226	0.000643	CcSEcCtD
Bosentan—Shock—Betamethasone—multiple sclerosis	0.000226	0.000641	CcSEcCtD
Bosentan—Shock—Dexamethasone—multiple sclerosis	0.000226	0.000641	CcSEcCtD
Bosentan—Dyspnoea—Triamcinolone—multiple sclerosis	0.000225	0.00064	CcSEcCtD
Bosentan—Nervous system disorder—Betamethasone—multiple sclerosis	0.000225	0.000639	CcSEcCtD
Bosentan—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000225	0.000639	CcSEcCtD
Bosentan—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000225	0.00154	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000225	0.00154	CbGpPWpGaD
Bosentan—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000225	0.000638	CcSEcCtD
Bosentan—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000225	0.000638	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—CNR1—multiple sclerosis	0.000224	0.00153	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000224	0.00153	CbGpPWpGaD
Bosentan—Tachycardia—Dexamethasone—multiple sclerosis	0.000224	0.000636	CcSEcCtD
Bosentan—Tachycardia—Betamethasone—multiple sclerosis	0.000224	0.000636	CcSEcCtD
Bosentan—Angioedema—Prednisone—multiple sclerosis	0.000224	0.000635	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CXCL13—multiple sclerosis	0.000223	0.00152	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCR1—multiple sclerosis	0.000223	0.00152	CbGpPWpGaD
Bosentan—Dyspepsia—Triamcinolone—multiple sclerosis	0.000222	0.000632	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000222	0.00152	CbGpPWpGaD
Bosentan—Erythema multiforme—Methotrexate—multiple sclerosis	0.000222	0.000631	CcSEcCtD
Bosentan—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000222	0.000631	CcSEcCtD
Bosentan—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000222	0.00063	CcSEcCtD
Bosentan—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000222	0.00063	CcSEcCtD
Bosentan—Vertigo—Prednisone—multiple sclerosis	0.00022	0.000625	CcSEcCtD
Bosentan—Eye disorder—Methotrexate—multiple sclerosis	0.00022	0.000624	CcSEcCtD
Bosentan—Syncope—Prednisone—multiple sclerosis	0.000219	0.000624	CcSEcCtD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000219	0.0015	CbGpPWpGaD
Bosentan—Tinnitus—Methotrexate—multiple sclerosis	0.000219	0.000622	CcSEcCtD
Bosentan—Anorexia—Betamethasone—multiple sclerosis	0.000219	0.000621	CcSEcCtD
Bosentan—Anorexia—Dexamethasone—multiple sclerosis	0.000219	0.000621	CcSEcCtD
Bosentan—Urticaria—Prednisolone—multiple sclerosis	0.000218	0.00062	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—CCR5—multiple sclerosis	0.000218	0.00149	CbGpPWpGaD
Bosentan—Cardiac disorder—Methotrexate—multiple sclerosis	0.000218	0.00062	CcSEcCtD
Bosentan—Fatigue—Triamcinolone—multiple sclerosis	0.000218	0.000619	CcSEcCtD
Bosentan—Fatigue—Methylprednisolone—multiple sclerosis	0.000217	0.000618	CcSEcCtD
Bosentan—Pain—Triamcinolone—multiple sclerosis	0.000216	0.000614	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—S1PR1—multiple sclerosis	0.000216	0.00148	CbGpPWpGaD
Bosentan—Loss of consciousness—Prednisone—multiple sclerosis	0.000215	0.000611	CcSEcCtD
Bosentan—Hypotension—Dexamethasone—multiple sclerosis	0.000214	0.000609	CcSEcCtD
Bosentan—Hypotension—Betamethasone—multiple sclerosis	0.000214	0.000609	CcSEcCtD
Bosentan—Angiopathy—Methotrexate—multiple sclerosis	0.000213	0.000606	CcSEcCtD
Bosentan—Vomiting—Mitoxantrone—multiple sclerosis	0.000213	0.000605	CcSEcCtD
Bosentan—Immune system disorder—Methotrexate—multiple sclerosis	0.000212	0.000603	CcSEcCtD
Bosentan—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000212	0.000602	CcSEcCtD
Bosentan—Rash—Mitoxantrone—multiple sclerosis	0.000211	0.0006	CcSEcCtD
Bosentan—Dermatitis—Mitoxantrone—multiple sclerosis	0.000211	0.0006	CcSEcCtD
Bosentan—Chills—Methotrexate—multiple sclerosis	0.000211	0.000599	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—GPC5—multiple sclerosis	0.00021	0.00144	CbGpPWpGaD
Bosentan—Headache—Mitoxantrone—multiple sclerosis	0.00021	0.000596	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000209	0.000594	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000209	0.000594	CcSEcCtD
Bosentan—Arthralgia—Prednisone—multiple sclerosis	0.000208	0.000592	CcSEcCtD
Bosentan—Anxiety—Prednisone—multiple sclerosis	0.000208	0.00059	CcSEcCtD
Bosentan—Insomnia—Betamethasone—multiple sclerosis	0.000207	0.000589	CcSEcCtD
Bosentan—Insomnia—Dexamethasone—multiple sclerosis	0.000207	0.000589	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000207	0.000588	CcSEcCtD
Bosentan—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000206	0.000586	CcSEcCtD
Bosentan—Paraesthesia—Dexamethasone—multiple sclerosis	0.000206	0.000585	CcSEcCtD
Bosentan—Paraesthesia—Betamethasone—multiple sclerosis	0.000206	0.000585	CcSEcCtD
Bosentan—Discomfort—Prednisone—multiple sclerosis	0.000206	0.000585	CcSEcCtD
Bosentan—Mental disorder—Methotrexate—multiple sclerosis	0.000206	0.000585	CcSEcCtD
Bosentan—Erythema—Methotrexate—multiple sclerosis	0.000205	0.000581	CcSEcCtD
Bosentan—Malnutrition—Methotrexate—multiple sclerosis	0.000205	0.000581	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000204	0.00139	CbGpPWpGaD
Bosentan—Hypersensitivity—Prednisolone—multiple sclerosis	0.000203	0.000575	CcSEcCtD
Bosentan—Dyspepsia—Dexamethasone—multiple sclerosis	0.000202	0.000574	CcSEcCtD
Bosentan—Dyspepsia—Betamethasone—multiple sclerosis	0.000202	0.000574	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—CXCL10—multiple sclerosis	0.000202	0.00138	CbGpPWpGaD
Bosentan—Urticaria—Triamcinolone—multiple sclerosis	0.000201	0.000571	CcSEcCtD
Bosentan—Urticaria—Methylprednisolone—multiple sclerosis	0.0002	0.000569	CcSEcCtD
Bosentan—Body temperature increased—Triamcinolone—multiple sclerosis	0.0002	0.000568	CcSEcCtD
Bosentan—Anaphylactic shock—Prednisone—multiple sclerosis	0.0002	0.000568	CcSEcCtD
Bosentan—Oedema—Prednisone—multiple sclerosis	0.0002	0.000568	CcSEcCtD
Bosentan—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000199	0.000566	CcSEcCtD
Bosentan—Decreased appetite—Dexamethasone—multiple sclerosis	0.000199	0.000566	CcSEcCtD
Bosentan—Decreased appetite—Betamethasone—multiple sclerosis	0.000199	0.000566	CcSEcCtD
Bosentan—Nausea—Mitoxantrone—multiple sclerosis	0.000199	0.000565	CcSEcCtD
Bosentan—Infection—Prednisone—multiple sclerosis	0.000198	0.000564	CcSEcCtD
Bosentan—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000198	0.000563	CcSEcCtD
Bosentan—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000198	0.000563	CcSEcCtD
Bosentan—Back pain—Methotrexate—multiple sclerosis	0.000198	0.000562	CcSEcCtD
Bosentan—Fatigue—Betamethasone—multiple sclerosis	0.000198	0.000562	CcSEcCtD
Bosentan—Fatigue—Dexamethasone—multiple sclerosis	0.000198	0.000562	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000197	0.00134	CbGpPWpGaD
Bosentan—Shock—Prednisone—multiple sclerosis	0.000197	0.000558	CcSEcCtD
Bosentan—Pain—Betamethasone—multiple sclerosis	0.000196	0.000557	CcSEcCtD
Bosentan—Pain—Dexamethasone—multiple sclerosis	0.000196	0.000557	CcSEcCtD
Bosentan—Nervous system disorder—Prednisone—multiple sclerosis	0.000196	0.000557	CcSEcCtD
Bosentan—Tachycardia—Prednisone—multiple sclerosis	0.000195	0.000554	CcSEcCtD
Bosentan—Skin disorder—Prednisone—multiple sclerosis	0.000194	0.000551	CcSEcCtD
Bosentan—Hyperhidrosis—Prednisone—multiple sclerosis	0.000193	0.000549	CcSEcCtD
Bosentan—Vision blurred—Methotrexate—multiple sclerosis	0.000193	0.000548	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—CCL3—multiple sclerosis	0.000192	0.00131	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CCR2—multiple sclerosis	0.000191	0.00131	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CCL5—multiple sclerosis	0.000191	0.00131	CbGpPWpGaD
Bosentan—Anorexia—Prednisone—multiple sclerosis	0.00019	0.000541	CcSEcCtD
Bosentan—Anaemia—Methotrexate—multiple sclerosis	0.000189	0.000537	CcSEcCtD
Bosentan—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000188	0.000533	CcSEcCtD
Bosentan—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000188	0.000533	CcSEcCtD
Bosentan—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000186	0.000529	CcSEcCtD
Bosentan—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000186	0.000528	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—PTGER4—multiple sclerosis	0.000185	0.00126	CbGpPWpGaD
Bosentan—Vertigo—Methotrexate—multiple sclerosis	0.000184	0.000522	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—RGS1—multiple sclerosis	0.000184	0.00125	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000184	0.00125	CbGpPWpGaD
Bosentan—Leukopenia—Methotrexate—multiple sclerosis	0.000183	0.00052	CcSEcCtD
Bosentan—Urticaria—Betamethasone—multiple sclerosis	0.000182	0.000518	CcSEcCtD
Bosentan—Urticaria—Dexamethasone—multiple sclerosis	0.000182	0.000518	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000182	0.000517	CcSEcCtD
Bosentan—Dizziness—Prednisolone—multiple sclerosis	0.000182	0.000516	CcSEcCtD
Bosentan—Asthenia—Triamcinolone—multiple sclerosis	0.000181	0.000515	CcSEcCtD
Bosentan—Body temperature increased—Betamethasone—multiple sclerosis	0.000181	0.000515	CcSEcCtD
Bosentan—Abdominal pain—Dexamethasone—multiple sclerosis	0.000181	0.000515	CcSEcCtD
Bosentan—Abdominal pain—Betamethasone—multiple sclerosis	0.000181	0.000515	CcSEcCtD
Bosentan—Body temperature increased—Dexamethasone—multiple sclerosis	0.000181	0.000515	CcSEcCtD
Bosentan—Asthenia—Methylprednisolone—multiple sclerosis	0.000181	0.000514	CcSEcCtD
Bosentan—Insomnia—Prednisone—multiple sclerosis	0.000181	0.000513	CcSEcCtD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000181	0.00123	CbGpPWpGaD
Bosentan—Paraesthesia—Prednisone—multiple sclerosis	0.000179	0.00051	CcSEcCtD
Bosentan—Pruritus—Triamcinolone—multiple sclerosis	0.000179	0.000508	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—CXCR3—multiple sclerosis	0.000179	0.00122	CbGpPWpGaD
Bosentan—Cough—Methotrexate—multiple sclerosis	0.000178	0.000507	CcSEcCtD
Bosentan—Pruritus—Methylprednisolone—multiple sclerosis	0.000178	0.000507	CcSEcCtD
Bosentan—ABCB11—Metabolism—CYP24A1—multiple sclerosis	0.000177	0.00121	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP27B1—multiple sclerosis	0.000177	0.00121	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CNR1—multiple sclerosis	0.000177	0.00121	CbGpPWpGaD
Bosentan—Dyspepsia—Prednisone—multiple sclerosis	0.000176	0.0005	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—GPR65—multiple sclerosis	0.000174	0.00119	CbGpPWpGaD
Bosentan—Arthralgia—Methotrexate—multiple sclerosis	0.000174	0.000495	CcSEcCtD
Bosentan—Chest pain—Methotrexate—multiple sclerosis	0.000174	0.000495	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—CCR2—multiple sclerosis	0.000174	0.00119	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CCL5—multiple sclerosis	0.000174	0.00119	CbGpPWpGaD
Bosentan—Decreased appetite—Prednisone—multiple sclerosis	0.000174	0.000493	CcSEcCtD
Bosentan—Rash—Prednisolone—multiple sclerosis	0.000173	0.000492	CcSEcCtD
Bosentan—Dermatitis—Prednisolone—multiple sclerosis	0.000173	0.000492	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000173	0.00118	CbGpPWpGaD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000173	0.000491	CcSEcCtD
Bosentan—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000173	0.00049	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—CCR5—multiple sclerosis	0.000172	0.00118	CbGpPWpGaD
Bosentan—Fatigue—Prednisone—multiple sclerosis	0.000172	0.000489	CcSEcCtD
Bosentan—Headache—Prednisolone—multiple sclerosis	0.000172	0.000489	CcSEcCtD
Bosentan—Discomfort—Methotrexate—multiple sclerosis	0.000172	0.000489	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000171	0.00117	CbGpPWpGaD
Bosentan—Constipation—Prednisone—multiple sclerosis	0.000171	0.000485	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—POMC—multiple sclerosis	0.000171	0.00116	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—IL2RA—multiple sclerosis	0.00017	0.00116	CbGpPWpGaD
Bosentan—Dizziness—Triamcinolone—multiple sclerosis	0.000167	0.000475	CcSEcCtD
Bosentan—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000167	0.000474	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—CCL2—multiple sclerosis	0.000167	0.00114	CbGpPWpGaD
Bosentan—Dizziness—Methylprednisolone—multiple sclerosis	0.000167	0.000474	CcSEcCtD
Bosentan—Infection—Methotrexate—multiple sclerosis	0.000166	0.000471	CcSEcCtD
Bosentan—Asthenia—Dexamethasone—multiple sclerosis	0.000165	0.000468	CcSEcCtD
Bosentan—Asthenia—Betamethasone—multiple sclerosis	0.000165	0.000468	CcSEcCtD
Bosentan—Nervous system disorder—Methotrexate—multiple sclerosis	0.000164	0.000465	CcSEcCtD
Bosentan—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000163	0.000464	CcSEcCtD
Bosentan—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000163	0.000464	CcSEcCtD
Bosentan—Nausea—Prednisolone—multiple sclerosis	0.000163	0.000464	CcSEcCtD
Bosentan—Pruritus—Betamethasone—multiple sclerosis	0.000162	0.000461	CcSEcCtD
Bosentan—Pruritus—Dexamethasone—multiple sclerosis	0.000162	0.000461	CcSEcCtD
Bosentan—Skin disorder—Methotrexate—multiple sclerosis	0.000162	0.000461	CcSEcCtD
Bosentan—ABCB11—Metabolism—GPC5—multiple sclerosis	0.000162	0.00111	CbGpPWpGaD
Bosentan—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000161	0.000459	CcSEcCtD
Bosentan—Vomiting—Triamcinolone—multiple sclerosis	0.000161	0.000457	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—CNR1—multiple sclerosis	0.00016	0.00109	CbGpPWpGaD
Bosentan—Vomiting—Methylprednisolone—multiple sclerosis	0.00016	0.000456	CcSEcCtD
Bosentan—Rash—Triamcinolone—multiple sclerosis	0.000159	0.000453	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CCR1—multiple sclerosis	0.000159	0.00109	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CXCL13—multiple sclerosis	0.000159	0.00109	CbGpPWpGaD
Bosentan—Dermatitis—Triamcinolone—multiple sclerosis	0.000159	0.000452	CcSEcCtD
Bosentan—Anorexia—Methotrexate—multiple sclerosis	0.000159	0.000452	CcSEcCtD
Bosentan—Rash—Methylprednisolone—multiple sclerosis	0.000159	0.000452	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000159	0.00109	CbGpPWpGaD
Bosentan—Dermatitis—Methylprednisolone—multiple sclerosis	0.000159	0.000451	CcSEcCtD
Bosentan—Urticaria—Prednisone—multiple sclerosis	0.000159	0.000451	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CCL3—multiple sclerosis	0.000159	0.00108	CbGpPWpGaD
Bosentan—Headache—Triamcinolone—multiple sclerosis	0.000158	0.00045	CcSEcCtD
Bosentan—Headache—Methylprednisolone—multiple sclerosis	0.000158	0.000449	CcSEcCtD
Bosentan—Abdominal pain—Prednisone—multiple sclerosis	0.000158	0.000449	CcSEcCtD
Bosentan—Body temperature increased—Prednisone—multiple sclerosis	0.000158	0.000449	CcSEcCtD
Bosentan—Diarrhoea—Dexamethasone—multiple sclerosis	0.000157	0.000446	CcSEcCtD
Bosentan—Diarrhoea—Betamethasone—multiple sclerosis	0.000157	0.000446	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—CCR5—multiple sclerosis	0.000156	0.00107	CbGpPWpGaD
Bosentan—Hypotension—Methotrexate—multiple sclerosis	0.000156	0.000443	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—IL2RA—multiple sclerosis	0.000154	0.00105	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTGER4—multiple sclerosis	0.000153	0.00104	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000152	0.000432	CcSEcCtD
Bosentan—Dizziness—Betamethasone—multiple sclerosis	0.000152	0.000431	CcSEcCtD
Bosentan—Dizziness—Dexamethasone—multiple sclerosis	0.000152	0.000431	CcSEcCtD
Bosentan—Insomnia—Methotrexate—multiple sclerosis	0.000151	0.000429	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—PGR—multiple sclerosis	0.00015	0.00103	CbGpPWpGaD
Bosentan—Nausea—Triamcinolone—multiple sclerosis	0.00015	0.000427	CcSEcCtD
Bosentan—Paraesthesia—Methotrexate—multiple sclerosis	0.00015	0.000426	CcSEcCtD
Bosentan—Nausea—Methylprednisolone—multiple sclerosis	0.00015	0.000426	CcSEcCtD
Bosentan—Dyspnoea—Methotrexate—multiple sclerosis	0.000149	0.000423	CcSEcCtD
Bosentan—Somnolence—Methotrexate—multiple sclerosis	0.000148	0.000422	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CXCR3—multiple sclerosis	0.000147	0.00101	CbGpPWpGaD
Bosentan—Hypersensitivity—Prednisone—multiple sclerosis	0.000147	0.000418	CcSEcCtD
Bosentan—Dyspepsia—Methotrexate—multiple sclerosis	0.000147	0.000417	CcSEcCtD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000146	0.001	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CD28—multiple sclerosis	0.000146	0.000997	CbGpPWpGaD
Bosentan—Vomiting—Betamethasone—multiple sclerosis	0.000146	0.000414	CcSEcCtD
Bosentan—Vomiting—Dexamethasone—multiple sclerosis	0.000146	0.000414	CcSEcCtD
Bosentan—Decreased appetite—Methotrexate—multiple sclerosis	0.000145	0.000412	CcSEcCtD
Bosentan—Rash—Betamethasone—multiple sclerosis	0.000145	0.000411	CcSEcCtD
Bosentan—Rash—Dexamethasone—multiple sclerosis	0.000145	0.000411	CcSEcCtD
Bosentan—Dermatitis—Dexamethasone—multiple sclerosis	0.000144	0.000411	CcSEcCtD
Bosentan—Dermatitis—Betamethasone—multiple sclerosis	0.000144	0.000411	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—CXCL10—multiple sclerosis	0.000144	0.000986	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000144	0.000409	CcSEcCtD
Bosentan—Fatigue—Methotrexate—multiple sclerosis	0.000144	0.000409	CcSEcCtD
Bosentan—Headache—Betamethasone—multiple sclerosis	0.000144	0.000408	CcSEcCtD
Bosentan—Headache—Dexamethasone—multiple sclerosis	0.000144	0.000408	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CCR2—multiple sclerosis	0.000143	0.000979	CbGpPWpGaD
Bosentan—Asthenia—Prednisone—multiple sclerosis	0.000143	0.000407	CcSEcCtD
Bosentan—Pain—Methotrexate—multiple sclerosis	0.000143	0.000406	CcSEcCtD
Bosentan—Pruritus—Prednisone—multiple sclerosis	0.000141	0.000402	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—CCL5—multiple sclerosis	0.000137	0.000934	CbGpPWpGaD
Bosentan—Diarrhoea—Prednisone—multiple sclerosis	0.000137	0.000388	CcSEcCtD
Bosentan—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000136	0.000388	CcSEcCtD
Bosentan—Nausea—Dexamethasone—multiple sclerosis	0.000136	0.000387	CcSEcCtD
Bosentan—Nausea—Betamethasone—multiple sclerosis	0.000136	0.000387	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—POMC—multiple sclerosis	0.000135	0.000919	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—RRM1—multiple sclerosis	0.000134	0.000916	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000133	0.000907	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000133	0.000907	CbGpPWpGaD
Bosentan—Urticaria—Methotrexate—multiple sclerosis	0.000133	0.000377	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CNR1—multiple sclerosis	0.000132	0.000904	CbGpPWpGaD
Bosentan—Dizziness—Prednisone—multiple sclerosis	0.000132	0.000375	CcSEcCtD
Bosentan—Abdominal pain—Methotrexate—multiple sclerosis	0.000132	0.000375	CcSEcCtD
Bosentan—Body temperature increased—Methotrexate—multiple sclerosis	0.000132	0.000375	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000131	0.000897	CbGpPWpGaD
Bosentan—Vomiting—Prednisone—multiple sclerosis	0.000127	0.000361	CcSEcCtD
Bosentan—Rash—Prednisone—multiple sclerosis	0.000126	0.000358	CcSEcCtD
Bosentan—Dermatitis—Prednisone—multiple sclerosis	0.000126	0.000357	CcSEcCtD
Bosentan—Headache—Prednisone—multiple sclerosis	0.000125	0.000356	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—CCL5—multiple sclerosis	0.000124	0.000849	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CCR5—multiple sclerosis	0.000123	0.000842	CbGpPWpGaD
Bosentan—Hypersensitivity—Methotrexate—multiple sclerosis	0.000123	0.000349	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—POMC—multiple sclerosis	0.000122	0.000835	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000122	0.00083	CbGpPWpGaD
Bosentan—Asthenia—Methotrexate—multiple sclerosis	0.00012	0.00034	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—CCL2—multiple sclerosis	0.00012	0.000817	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CXCL10—multiple sclerosis	0.000119	0.000814	CbGpPWpGaD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000119	0.000813	CbGpPWpGaD
Bosentan—Nausea—Prednisone—multiple sclerosis	0.000119	0.000337	CcSEcCtD
Bosentan—Pruritus—Methotrexate—multiple sclerosis	0.000118	0.000336	CcSEcCtD
Bosentan—Diarrhoea—Methotrexate—multiple sclerosis	0.000114	0.000325	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CCL3—multiple sclerosis	0.000114	0.000775	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CCR5—multiple sclerosis	0.000112	0.000764	CbGpPWpGaD
Bosentan—Dizziness—Methotrexate—multiple sclerosis	0.00011	0.000314	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—IL2RA—multiple sclerosis	0.00011	0.000753	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTGER4—multiple sclerosis	0.000109	0.000746	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—TYK2—multiple sclerosis	0.000109	0.000742	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PGR—multiple sclerosis	0.000108	0.000735	CbGpPWpGaD
Bosentan—Vomiting—Methotrexate—multiple sclerosis	0.000106	0.000302	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CXCR3—multiple sclerosis	0.000106	0.00072	CbGpPWpGaD
Bosentan—Rash—Methotrexate—multiple sclerosis	0.000105	0.000299	CcSEcCtD
Bosentan—Dermatitis—Methotrexate—multiple sclerosis	0.000105	0.000299	CcSEcCtD
Bosentan—Headache—Methotrexate—multiple sclerosis	0.000105	0.000297	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CD28—multiple sclerosis	0.000105	0.000714	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CD86—multiple sclerosis	0.000104	0.000711	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000104	0.000711	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCR2—multiple sclerosis	0.000103	0.000701	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCL5—multiple sclerosis	0.000103	0.0007	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—IL2—multiple sclerosis	9.96e-05	0.00068	CbGpPWpGaD
Bosentan—Nausea—Methotrexate—multiple sclerosis	9.91e-05	0.000282	CcSEcCtD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	9.66e-05	0.000659	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—POMC—multiple sclerosis	9.64e-05	0.000658	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SPP1—multiple sclerosis	9.5e-05	0.000649	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CNR1—multiple sclerosis	9.47e-05	0.000647	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCR5—multiple sclerosis	9.24e-05	0.000631	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL2RA—multiple sclerosis	9.11e-05	0.000622	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—IL2—multiple sclerosis	9.04e-05	0.000617	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.95e-05	0.000611	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—POMC—multiple sclerosis	8.75e-05	0.000597	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CCL2—multiple sclerosis	8.56e-05	0.000585	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CXCL10—multiple sclerosis	8.53e-05	0.000582	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—APOE—multiple sclerosis	8.41e-05	0.000574	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SRM—multiple sclerosis	8.39e-05	0.000573	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.16e-05	0.000557	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—POMC—multiple sclerosis	7.78e-05	0.000531	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—TYK2—multiple sclerosis	7.78e-05	0.000531	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—BCHE—multiple sclerosis	7.71e-05	0.000526	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CD80—multiple sclerosis	7.6e-05	0.000519	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CD86—multiple sclerosis	7.46e-05	0.000509	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCL5—multiple sclerosis	7.34e-05	0.000501	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—POMC—multiple sclerosis	7.22e-05	0.000493	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—IL2—multiple sclerosis	7.12e-05	0.000486	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCL2—multiple sclerosis	7.07e-05	0.000483	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—MAPK1—multiple sclerosis	6.92e-05	0.000472	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SPP1—multiple sclerosis	6.8e-05	0.000464	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCR5—multiple sclerosis	6.62e-05	0.000452	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL2RA—multiple sclerosis	6.52e-05	0.000445	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL2—multiple sclerosis	6.47e-05	0.000442	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TYK2—multiple sclerosis	6.42e-05	0.000438	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—APOE—multiple sclerosis	6.02e-05	0.000411	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	5.91e-05	0.000404	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	5.91e-05	0.000404	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	5.78e-05	0.000395	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SRM—multiple sclerosis	5.54e-05	0.000378	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CD80—multiple sclerosis	5.44e-05	0.000371	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GPC5—multiple sclerosis	5.41e-05	0.000369	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL2—multiple sclerosis	5.34e-05	0.000365	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—IL6—multiple sclerosis	5.31e-05	0.000363	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—POMC—multiple sclerosis	5.17e-05	0.000353	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—POMC—multiple sclerosis	5.13e-05	0.00035	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCL2—multiple sclerosis	5.06e-05	0.000345	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MMP9—multiple sclerosis	5.05e-05	0.000345	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—MAPK1—multiple sclerosis	4.95e-05	0.000338	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—APOE—multiple sclerosis	4.64e-05	0.000317	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TYK2—multiple sclerosis	4.59e-05	0.000314	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—STAT3—multiple sclerosis	4.49e-05	0.000307	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—RRM1—multiple sclerosis	4.48e-05	0.000306	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MYC—multiple sclerosis	4.18e-05	0.000285	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TGFB1—multiple sclerosis	4.17e-05	0.000284	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MAPK1—multiple sclerosis	4.09e-05	0.000279	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—POMC—multiple sclerosis	3.98e-05	0.000272	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	3.9e-05	0.000266	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	3.9e-05	0.000266	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL2—multiple sclerosis	3.82e-05	0.000261	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL6—multiple sclerosis	3.8e-05	0.00026	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ALB—multiple sclerosis	3.63e-05	0.000248	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MMP9—multiple sclerosis	3.62e-05	0.000247	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GPC5—multiple sclerosis	3.57e-05	0.000244	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.48e-05	0.000237	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—STAT3—multiple sclerosis	3.22e-05	0.00022	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL6—multiple sclerosis	3.14e-05	0.000214	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MYC—multiple sclerosis	2.99e-05	0.000204	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.99e-05	0.000204	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TGFB1—multiple sclerosis	2.98e-05	0.000204	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.96e-05	0.000202	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAPK1—multiple sclerosis	2.92e-05	0.0002	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.72e-05	0.000186	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—BCHE—multiple sclerosis	2.57e-05	0.000176	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL6—multiple sclerosis	2.25e-05	0.000153	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.7e-05	0.000116	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—APOE—multiple sclerosis	1.55e-05	0.000106	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—POMC—multiple sclerosis	1.33e-05	9.08e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALB—multiple sclerosis	1.21e-05	8.28e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—APOE—multiple sclerosis	1.02e-05	6.97e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—POMC—multiple sclerosis	8.77e-06	5.99e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALB—multiple sclerosis	8e-06	5.46e-05	CbGpPWpGaD
